Posts

Novo Nordisk hit by multi‑million‑dollar ransom demands after major data breach claimed by hacking groups

on

Novo Nordisk Q1: Pills, Pricing, Payments, Pressure

on

Recent Pharma News: Novo Nordisk's Oral Semaglutide for Kids, Altimmune $225M Offering, Merck-Google Cloud Partnership

on

Novo Nordisk's Etavopivat Achieves Positive Phase 3 Results in Sickle Cell Disease Trial

on

Novo Nordisk Prepares Etavopivat for SCD Approval After Phase 3 Success and $1.1B Forma Acquisition

on

Novo Nordisk Partners with OpenAI to Accelerate Drug Development

on

Novo Nordisk Faces Double Departures: GLP-1 Expert Retires as Obesity Leader Joins Boehringer Ingelheim

on

Novo Nordisk Launches Discounted Multi-Month Subscription Program for Wegovy via Telehealth Providers

on

Novo Nordisk to Cut 400 Jobs at Bloomington, Indiana Facility Amid Prior Ownership Layoffs

on

No Recent NICE Cardio Approval for Wegovy

on

Novo Nordisk Launches Discounted Subscription Program for Wegovy

on

Novo Nordisk's GLP-1 Pipeline Advances with Oral Innovations Amid Analyst Concerns on Oral Trends

on

Novo Nordisk's Triple-G Agonist UBT251 Achieves 19.7% Weight Loss in Phase 2 Trial in China

on

Novo Nordisk's High-Dose Wegovy Receives FDA Approval Under Commissioner's Voucher Program

on

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

on

Hims Agrees to Limit Compounding, Ending Legal Dispute with Novo Nordisk

on

Novo Nordisk Partners with Langer-Founded Vivtex on Oral Obesity Drugs in $2.1B Deal

on

Novo Nordisk Announces 50% Wegovy List Price Cut to $675 Starting January 2027

on

Novo Nordisk's CagriSema Underperforms Eli Lilly's Zepbound in Head-to-Head Phase 3 Obesity Trial

on

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

on